Has Christopher Tarnay, MD received payments from drug or device companies?

Yes. Drug and device makers reported $40,704 in general payments to Christopher Tarnay, MD across 135 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christopher Tarnay, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christopher Tarnay, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christopher Tarnay, MD

Urogynecology and Reconstructive Pelvic Surgery · Los Angeles, CANPI 1780619221

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $29,070 of the $40,704 with a category attached, or 71.4%. Boston Scientific accounts for 85.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $15,315 and has fallen 90.0% since, to $1,527 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$40,704in general payments, 2019–2025

Across 135 payments — averaging $301.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$35K
Medtronic$4K
Coloplast$1K
AbbVie$459
Intuitive Surgical$145
Caldera Medical, Inc$107
plus $51 from 1 others

$61,272in research payments, 2019–2025

Across 21 payments — averaging $2917.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Cook Research Incorporated$61K

What the payments were for

Consulting fees$7612%
Speaking & faculty fees$29,07071%
Grants$1210%
Travel & lodging$3,0187%
Food & beverage$7,33818%
Education$3951%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	48	$34,861
Medtronic(2 entities)	52	$3,952
Coloplast	13	$1,129
AbbVie	14	$459
Intuitive Surgical	5	$145
Caldera Medical, Inc	1	$107
Teleflex LLC	2	$51

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,704 in reported general payments places this provider in the 90th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.

See all urogynecology and reconstructive pelvic surgery providers in California →

Medicare billing

Part B allowed, 2024

$201,563

Medicare patients

427

Services billed

2,941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
GemtesaVibegron	51	$37,803
MyrbetriqMirabegron	31	$36,501
PremarinEstrogens, Conjugated	53	$23,606
Estradiol	35	$2,155
DottiEstradiol	12	$644
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst	15	$131
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	35	$86

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Los Angeles

Tanaz FerzandiLos Angeles$60K
Anne AckermanLos Angeles$32K
Darlene MorrisseyLos Angeles$10K
Yoko BeanLos Angeles$9K
Victoria ScottLos Angeles$5K
Thinh DuongLos Angeles$5K
Victor VelascoLos Angeles$5K
Andrey PetrikovetsLos Angeles$5K
Atieh NovinLos Angeles$5K
Michele TorosisLos Angeles$5K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →